NCT01619865View on ClinicalTrials.gov

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

February 21, 2012

Primary Completion Date

August 27, 2017

Study Completion Date

August 27, 2017

Conditions
Neuroendocrine TumorsCarcinoid TumorsNeuroblastomaMedulloblastoma
Interventions
DRUG

68Ga-DOTATOC PET/CT

1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.

Trial Locations (1)

52242

University of Iowa Health Care, Iowa City

All Listed Sponsors
lead

Sue O'Dorisio

OTHER

NCT01619865 - Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors | Biotech Hunter | Biotech Hunter